期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非离子型表面活性剂HS 15在药剂中的研究进展 被引量：9

Research Progress of Nonionic Surfactant HS 15 in Pharmaceutical Preparations
原文传递
导出
摘要 KolliphorHS15(HS15)是一种新型注射用增溶剂,具有强大的增溶能力和优良的安全性,可用于提高药物的溶解度、促进吸收以及增加生物利用度。综述HS15在制剂中的应用、临床研究和基础研究进展,为其在药剂中的应用研究提供参考。 Kolliphor HS 15（HS 15） is a novel solubilizer for injections. With high solubilizing capacity and excellent safety, HS 15 has been used to increase drugs＇ solubility, enhance absorption and improve bioavailability. This paper reviewed the applications of HS 15 in marketed formulations as well as the progress in related clinical investigations and basic researches so as to provide reference for its application in pharmaceutical formulations.
作者 张蕾 訾鹏 高洁 张灿
机构地区 中国药科大学新药研究中心 巴斯夫(中国)有限公司
出处 《药学进展》 CAS 2015年第5期370-375,共6页 Progress in Pharmaceutical Sciences
关键词 Kolliphor^(■) HS15 注射剂安全性 临床研究 Kolliphor^(■) HS15 safety of injection clinical research
分类号 TQ460.4 [化学工程—制药化工]
  • 相关文献

参考文献28

  • 1Lee E I-t, Lee S H, Park D Y, et al. Physicochemical properties, pharmacokinetics, and pharmacodynamics of a rc|'ormulated mic- roemulsion propofol in rats[J]. Anesthesiolog3,, 2008, 109(3): 436-447.
  • 2Mira M M, Spear M A, Yee L K, et al. Phase 1 first-in-human trial of the vascular disrupting agent Plinabulin (NP1-2358) ill patients with solid tumors or lymp boreas[J]. ~'lin Cancer Res, 2010, 16(23): 5892-5899.
  • 3Millward M, Mainwaring P, Mira A, et al. Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel[J], lm'est New Drugs, 2(}12, 30(3): 1065-1073.
  • 4Mira A C, Heist R S, Aren O, et al. Phase II study of docetaxel with or without ptinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2010, 28(15): 7592-7592.
  • 5Sire J Y, Lee S H, Park D Y, et al. Pain on injection with microemulsion propofol [J]. Br J Clin Pharmacol, 2009, 67(3): 316-325.
  • 6Kim K M, Choi B M, Park S W, et al. Pharmacokinetics and phar- maeodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusion[J]. Anesthesiology, 2007, 106(5): 924-934.
  • 7Reid J M, Walden C A, Qin R, et al. Phase 0 clinical chemoprevention trial of the Akt inhibitor SRI3668[J]. Cancer Prey Res, 2011, 4(3): 347- 353.
  • 8Ilium L, Jordan F, Lewis A L. CriticalSorb: a novel efficient nasal delivery system IZ~r human growth hormone based on Solutol HS15 [J]. J Controlled Release, 2012, 162( I ): 194-200.
  • 9Brayden D J, Bzik V A, Lewis A L, et al. Critical Sorb'" promotes permeation of flux markers across isolated rat intestinal mucosae and Caco-2 monolayers[J]. Pharm Res, 2012, 29(9): 2543-2554.
  • 10Lu H, Li J, Li M, et ~1l. Systemic delivery of alpha-asarone with Kolliphor HS 15 improves its safety and therapeutic effect on asthma[J]. Drug Deliv, 2015, 22(3): 266-275.

二级参考文献76

共引文献38

同被引文献98

引证文献9

二级引证文献35

药学进展
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部